Better Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Better Therapeutics files for FDA approval of new type of digital therapy for diabetes
Sep 22Better Therapeutics GAAP EPS of -$0.42 in-line
Aug 11Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
May 12Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Nov 30CEO
Better Therapeutics has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.6yrs | US$119.25k | 35.58% $ 1.9k | |
| Interim CFO | 1.5yrs | US$557.50k | 0.85% $ 46.4 | |
| Chief Medical Officer | 3.6yrs | US$593.70k | 0.59% $ 32.1 | |
| Chief Product Officer | 3.6yrs | US$558.70k | 0.37% $ 20.0 | |
| Senior VP of Technology & Head of Engineering | no data | no data | no data | |
| Senior Vice President of Market Access | 1.8yrs | no data | no data | |
| Chief Commercial Officer | 1.3yrs | no data | no data | |
| Controller | no data | no data | 0.026% $ 1.4 |
Experienced Management: BTTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.6yrs | US$119.25k | 35.58% $ 1.9k | |
| Independent Director | 3.6yrs | US$36.09k | 1.36% $ 74.2 | |
| Independent Director | 3.6yrs | US$159.56k | 0.28% $ 15.4 | |
| Independent Director | 3.6yrs | US$36.34k | 1.98% $ 108.1 | |
| Independent Director | 3.5yrs | US$32.34k | 0.066% $ 3.6 |
Experienced Board: BTTX's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 14:03 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Better Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Rahul Rakhit | LifeSci Capital, LLC |